Reuters logo
BRIEF-Serodus says primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy
January 2, 2017 / 11:43 AM / in a year

BRIEF-Serodus says primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy

Jan 2 (Reuters) - Serodus ASA :

* Says primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy

* No safety issues were identified in Phase 2a study of SER150 in patients with Diabetic Nephropathy, and that strong trend towards reduced protein excretion in urine was observed

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below